Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZGGS18 in advanced solid tumors
CTR20222300Phase 2Active
- Sponsor
- Zelgen
- Start
- Nov 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ZGGS18 in Nonhematologic neoplasms, osteosarcoma (OS), colorectal cancer (CRC) and 3 more, sponsored by Zelgen. Primary endpoints: Dose-limiting toxicity, Safety and tolerability and 2 more. Started Nov 2022; status: active.
02
Drugs
ZGGS18
03
Conditions
Nonhematologic neoplasmsosteosarcoma (OS)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)gastric adenocarcinoma
Beyond the preview
Go deeper on CTR20222300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222300.